[Excerpt from HFA’s “Voluntary Recall of Altuviiio lot #EY0330” notification]
The Hemophilia Federation of America has become aware of a voluntary non-life-threatening recall of Altuviiio lot #EY0330 due to incorrect labeling on dose potency affecting one lot of product. Sanofi has notified US medical providers under MASAC Medical Advisory # 430 about the voluntary recall, and we have included a statement from the California Board of Pharmacy here with more information.
While Sanofi has indicated that there should be no impacts to clinical outcomes due to this mislabeling, we encourage you to reach out to your medical provider with any questions or concerns. Please sign up for the Patient Notification System (PNS) to receive direct notifications about the latest recalls or withdrawals of recombinant and plasma products here: http://www.patientnotificationsystem.org
HFA will continue to update our community on changes to healthcare policy, access, and treatment, including potential issues and recalls of medication. Be sure to follow them and join HFA to stay up to date on upcoming developments in the future.
